Amedisys INC

Amedisys, Inc. has completed its merger with UnitedHealth Group, becoming a wholly-owned subsidiary and delisting from Nasdaq, with shareholders receiving $101 per share in cash.

Amedisys and UnitedHealth Group reached a proposed final judgment with the U.S. Department of Justice and several states, clearing a significant hurdle for their merger, pending judicial approval and required divestitures.

Amedisys, Inc. announced increased adjusted revenue and profitability for the second quarter of 2025, despite a GAAP net income decline driven by significant merger-related expenses and ongoing regulatory challenges to its proposed acquisition by UnitedHealth Group.

Amedisys has entered into agreements to sell certain home health and hospice care centers to BrightSpring Health Services and The Pennant Group, contingent upon the completion of its merger with UnitedHealth Group.

Amedisys extends its credit facility maturity to July 2027 and reports increased net service revenue and adjusted EBITDA for the first quarter of 2025.

Amedisys reports a net loss for Q4 2024, impacted by merger-related expenses and impairment charges, while annual net income improves compared to the previous year.

Amedisys, a leading home health and hospice provider, reported increased net service revenue but a decline in three-month net income due to higher merger-related expenses, while six-month net income surged from a one-time gain, as its proposed merger with UnitedHealth Group faces continued antitrust challenges and a significant proposed Medicare payment reduction looms.

Amedisys reports its Q1 2025 financial results, showing increased revenue and operating income, while navigating the complexities of its pending merger with UnitedHealth Group and ongoing legal challenges.

Amedisys' Q3 2024 results show a decrease in operating income despite revenue growth, influenced by merger-related expenses and other factors.

Amedisys' second quarter results show increased revenue but also higher expenses, with the company navigating a pending merger with UnitedHealth Group and a cyber security incident impacting collections.

Amedisys' first quarter results show a decrease in operating income despite a revenue increase, impacted by merger-related expenses and a cybersecurity incident.

Amedisys files Amendment No. 2 to its Form 10-K to include information required by Part III and updated certifications from the CEO and CFO.

Amedisys files an amendment to its 2024 Annual Report to correct the number of outstanding shares of common stock as of February 21, 2025.

Amedisys files its 2024 10-K, detailing financial performance and ongoing merger uncertainties with UnitedHealth Group.

Amedisys has filed an amendment to its annual report on Form 10-K, primarily to include information required by Part III of the form, focusing on executive compensation, corporate governance, and related matters.

Amedisys is accelerating bonus payments and equity vesting for executives as part of a 280G mitigation strategy ahead of its merger with UnitedHealth Group.

Amedisys Director Molly Joel Coye reported the disposition of all her shares following the company's acquisition by UnitedHealth Group for $101 per share.

Amedisys Director Julie D. Klapstein disposed of all her shares following the company's acquisition by UnitedHealth Group for $101 per share in cash.

Amedisys Director Paul B. K. Kusserow's equity and derivative holdings in Amedisys Inc. were converted or disposed of following the acquisition by UnitedHealth Group on August 14, 2025.

Amedisys Director Jeffrey A. Rideout reported the disposition of all his shares following the company's acquisition by UnitedHealth Group for $101 per share in cash.

Amedisys, Inc. director Vickie L. Capps reports disposition of shares following the company's acquisition by UnitedHealth Group for $101 per share in cash.

Amedisys Chief Legal Officer Jennifer G. Griffin's equity holdings converted to cash and UnitedHealth Group securities following the acquisition.

Amedisys Inc. has released its proxy statement for the 2024 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Pentwater Capital Management LP and Matthew Halbower report 0% beneficial ownership in Amedisys Inc. common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC report a 0.0% beneficial ownership stake in Amedisys, Inc. common stock.

Pentwater Capital Management LP and Matthew Halbower have disclosed a passive 5.2% beneficial ownership stake in Amedisys Inc.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 5.4% in Amedisys, Inc. common stock.